Opdualag

Nivolumab;relatlimab-rmbw (Opdualag) has been approved for the treatment of adult and pediatric patients 12 years and older with unresectable or metastatic melanoma. Opdualag is a combiation of nivolumab, a monoclonal antibody that enhances the antitumor immune response by binding to the programmed death receptor-1 (PD-1) and blocking its interaction with ligand 1 and 2 (PD-L1 and PD-L2), and relatlimab, binds to the lymphocyte activation gene-3 (LAG-3) receptor which results in promoting T cell proliferation and cytokine secretion. The combined agents result in inhibition of tumor growth. <a id="